Among microbial expression hosts, Bacillus has carved out a unique niche in biomanufacturing. Unlike Gram-negative bacteria such as E. coli, Bacillus subtilis and related species are naturally endotoxin-free, simplifying downstream purification and expanding their appeal for therapeutic proteins, enzymes, and next-generation biologics. For a Contract Development and Manufacturing Organization (CDMO), mastery of Bacillus systems requires balancing its advantages—secretion capability, GRAS status, industrial […]
Tag: Klebsiella Pnemoniae
Overcoming Endotoxin Challenges in Therapeutic Phage Manufacturing: A CDMO Perspective
Endotoxin removal is one of the most persistent bottlenecks in bringing therapeutic bacteriophages to market. Produced by the outer membrane of Gram-negative bacteria, endotoxins (lipopolysaccharides, or LPS) can trigger severe immune reactions in patients if not reduced to ultra-low levels. For a Contract Development and Manufacturing Organization (CDMO), especially one producing phage therapies at GMP […]